Track market-moving stories before they get noisy

BEAVERTON, Ore.--(BUSINESS WIRE)--Digimarc Corporation (NASDAQ: DMRC), a leading provider of digital identity and authentication technologies, today announced strong market momentum for its gift card security solution following a highly successful week at the 2026 Retail Gift Card Association (RGCA) industry event in Denver, CO. Digimarc's cross-functional team of five experts specializing in retail technology, digital identity, and fraud prevention engaged in dozens of strategic discussions wi.

PALO ALTO, Calif.--(BUSINESS WIRE)--D-Wave Quantum Inc. (NASDAQ: QBTS), (“D-Wave” or the “Company”), the only dual-platform quantum computing company providing both annealing and gate-model systems, software, and services, today announced that management will be participating in the following investor conferences: 2026 Cantor Convergence Conference on November 11, 2026 in Miami, Florida BMO Technology and Innovation Leaders Conference on November 12, 2026 in New York City RBC Capital Markets Gl.

On October 26, 2026, we delve into the DCF analysis for The Toronto-Dominion Bank (TD), a financial institution that has shown impressive price performance rece

Elon Musk said that many neocloud companies face "guppy-level death." Bloomberg/Getty Images Neocloud companies are sliding even lower.

Shares dropped further on Monday after Elon Musk warned that many of them face "guppy-level death."

CoreWeave and Nebius have both fallen more than 30% over the past month, largely due to growing concerns about the debt they've taken on to build more data centers.

In early premarket trading on Monday, CoreWeave was down another 5%, and Nebius was down 3%, though those losses pared somewhat as the opening bell approached. Iren, another publicly traded neocloud, saw a near 3% premarket drop Monday.

The declines follow a string of X posts from Musk on Sunday evening questioning the neocloud business model.

"As of the past few weeks, debt markets have almost entirely shut off access to money for any company that doesn't have substantial revenue independent of AI data centers," he said.

"That means the 200+ neoclouds are going to see guppy-level death and consolidation," he added. "Some will make it through, but not many."

Musk said that while SpaceX has closed $40 billion in debt to buy GPUs, his company makes money through Starlink and rocket launches.

Meanwhile, investors are worried that a slowing AI boom could leave debt-heavy neoclouds struggling to service their loans.

After one X user posted arguing that Musk was trying to drive down the share prices of neocloud companies to acquire them, Musk replied: "SpaceX is not buying any neoclouds. Pointless."

Nvidia CEO Jensen Huang remains bullish about the sector. "The demand for the neoclouds is off the charts," he told CNBC last Thursday.

Nvidia holds significant stakes in CoreWeave, Nebius, and other cloud-computing companies.

However, a recent Bernstein Research report analyzed thousands of planned US data centers and estimated that only about 35% of the announced capacity will be built.

"Press releases are cheap … concrete is not," Bernstein analysts wrote in a research note.

Read next

Business Insider tells the innovative stories you want to know

Business Insider tells the innovative stories you want to know

Business Insider tells the innovative stories you want to know

Business Insider tells the innovative stories you want to know

Pete Syme You're currently following this author! Click to unsubscribe from email alerts.

Pete Syme is an aviation reporter for Business Insider, based in London.He writes about all things related to the industry, from aviation safety and CEO interviews to route reveals and airplane tours. Pete also uses data for industry analyses and to visualize breaking news events.Before joining Business Insider in 2022, he graduated with an MA in Newspaper Journalism from City, University of London, and a BA in English from the University of Exeter.

AI Elon Musk

Shares of major neocloud companies CoreWeave CRWV, Nebius and Iren fell during premarket trading on Monday after Elon Musk warned that more than 200 firms in the sector could face failures and consolidation as access to financing tightens. Iren shares fell roughly 3%, while CoreWeave dropped around 5% and Nebius declined more than 2%.

-

NEW YORK--(BUSINESS WIRE)--FuboTV Inc. (NYSE: FUBO) today announced that it will issue financial results for its fiscal full year and fourth quarter 2026 before the market opens on Tuesday, November 17, 2026.

Following the release, Fubo CEO Alisa Bowen and CFO John Janedis will host a conference call to review results and provide a business update.

Conference Call Details:
Date: Tuesday, November 17, 2026
Start Time: 9:30 a.m. ET

Dial-In Details:
North America (Toll-Free): 1-833-461-5787
International (Toll): +1-585-542-9983
Meeting ID: 556 358 593

The webcast will also be available on the Events & Presentations page of Fubo’s investor relations website. Participants should join the webcast 10 minutes in advance to ensure that they are connected prior to the event. An archived replay will be available on Fubo’s investor relations website following the call.

About FuboTV Inc.

FuboTV Inc. (NYSE: FUBO) is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming through a best-in-class user experience that offers greater choice, flexibility and value. The sixth largest Pay TV company in the U.S. (UBS estimates) and ranked among Fast Company’s Most Innovative Companies (2026) and the Financial Times’ The Americas’ Fastest-Growing Companies (2026, 2025), FuboTV Inc. owns Hulu + Live TV (entertainment), Fubo (sports) and Molotov (entertainment and sports), which stream in markets around the globe. FuboTV Inc. is an affiliate of The Walt Disney Company.

Learn more at https://fubo.tv

More News From fuboTV

Back to Newsroom

Bitmine repurchased 2.04 million shares in the past week Bitmine has repurchased a cumulative 22.9 million shares so far in 2026, the largest ever crypto treasury company equity buyback executed Bitmine owns 4.95% of the total ETH coin supply of 122.2 million Bitmine is 99% of the way to the 'Alchemy of 5%' in just 15 months Bitmine released Chairman's Message on October 7 titled "Crypto Bull Underway — This Cycle Likely the Largest" Bitmine was added to the Russell 1000 Large-cap index on June 26, 2026 Bitmine's Series A Preferred Stock is trading on the NYSE under the symbol BMNP Bitmine has 5,227,037 staked ETH, representing $12.3 billion at $2,356 per ETH. MAVAN (Made in America VAlidator Network) is a premier Ethereum staking destination for BMNR and institutional investors Bitmine owns $76 million of Eightco (NASDAQ: ORBS), now one of the only publicly listed equities in the world to provide investors indirect exposure to OpenAI Bitmine Crypto + Total Cash Holdings & Marketable Securities + "Moonshots" total $15 billion, including 6.05 million ETH tokens, total cash & marketable securities of $514 million, and other crypto holdings Bitmine remains supported by a premier group of institutional investors including ARK's Cathie Wood, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital and personal investor Thomas "Tom" Lee to support Bitmine's goal of acquiring 5% of ETH NORWALK, Conn.

SpaceX (NASDAQ:SPCX | SPCX Price Prediction) founder Elon Musk delivered a blunt warning to the companies that rent out AI computing power, and the selling it triggered is concentrated in a narrow slice of the market. CoreWeave (NASDAQ:CRWV) stock is…

SpaceX (NASDAQ:SPCX | SPCX Price Prediction) founder Elon Musk delivered a blunt warning to the companies that rent out AI computing power, and the selling it triggered is concentrated in a narrow slice of the market. CoreWeave (NASDAQ:CRWV) stock is at $51.62, down 5% in morning trading. For a company that leans heavily on borrowed money to build data centers, a warning about closed-off credit markets strikes at the core of its growth plan.

Meanwhile, IREN Limited (NASDAQ:IREN) stock is at $24.37, down 3% to $24.21. Nebius Group (NASDAQ:NBIS) stock trades at $155.50, down 2%.

Also, the First Trust Cloud Computing ETF (NASDAQ:SKYY) is at $167.42 and essentially unmoved. Large caps are stronger, with the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) at $762.07, up 0.3%. That gap limits the pressure to the neocloud corner.

Musk’s Credit Warning Rattles AI Cloud Renters In posts on X on October 25, Musk said debt markets have almost entirely shut off financing for companies without substantial revenue independent of AI data centers. He went further. He stated that neoclouds, the companies renting graphics processing unit (GPU) capacity to AI developers, face “guppy-level death and consolidation.” Musk named no company, so CoreWeave, IREN and Nebius shares are trading on the remarks as a verdict on debt-funded AI cloud models as a whole.

Asked whether he was trying to push the stocks down ahead of a buyout, Musk replied: “SpaceX is not buying any neoclouds. Pointless.” His answer takes a SpaceX deal off the table and leaves the financing argument as the core message for CoreWeave and its peers. CoreWeave’s bonds fell to distressed levels this month on concern over the debt funding the neocloud buildout, so the remarks land on a group already under credit pressure.

Nebius Holds Firm While CoreWeave and IREN Slide Both CoreWeave and Nebius rent GPU capacity to AI developers and fund much of their data center buildout with borrowed money. That model ties both stocks closely to credit conditions, which is exactly the pressure point Musk described in his posts. Yet, Nebius is inching higher while CoreWeave slips.

IREN came to AI cloud from cryptocurrency mining, so its data center capacity grew out of a different business than the two pure neoclouds. Its shares are still tracking CoreWeave stock lower, which shows that the mining origin hasn’t shielded IREN from the selling, and for now, IREN stock sits closer to CoreWeave stock than to Nebius stock in how traders are pricing Musk’s warning.

Within the First Trust Cloud Computing ETF, CoreWeave is one holding among a wide spread of software, networking and infrastructure names, which helps explain the fund’s flat reading. Nebius and IREN aren’t among the fund’s holdings, so the ETF offers no direct read on either name. The fund’s stability points to stress concentrated among a handful of GPU renters.

What Musk’s Warning Means for CoreWeave, IREN and Nebius CoreWeave’s next test is whether its bond prices stabilize as lenders reassess the neocloud group, and a recovery in those bonds would ease the credit worry weighing on CoreWeave shares, while further weakness could keep the stock under pressure. Musk warned the group as a whole. Because of that, stronger operators may still separate themselves if consolidation arrives, and we laid out how to ride an AI mania while planning the exit in a free handbook here.

For Nebius, the bull case is its contracted demand and its resilience while peers slide; the bear case is that it relies on the same borrowed money Musk called out. For IREN, bulls point to its AI cloud pivot and big-name customers, while bears note its shares are trading in lockstep with CoreWeave. Those with exposure to these neocloud stocks should keep their positions sized modestly given how tightly this group trades on credit conditions.

Contact [email protected] for any questions or corrections.

- Ongoing Pivotal Phase 3 trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel versus standard-of-care chemotherapy in first-line metastatic pancreatic cancer -

-MAPKeeper 301 builds on encouraging Phase 2a results presented at ASCO 2026 including median overall survival (OS) of 17.3 months -

- Global, randomized Phase 3 trial ongoing, with overall survival as the primary endpoint -

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that a trial-in-progress poster describing the design and methodology for MAPKeeper 301, its ongoing pivotal Phase 3 clinical trial evaluating atebimetinib in combination with modified gemcitabine and nab-paclitaxel (mGnP) in first-line metastatic pancreatic ductal adenocarcinoma (PDAC), was presented at the European Society for Medical Oncology (ESMO) Congress 2026 held October 23-27, 2026 in Madrid, Spain.

MAPKeeper 301 is a global, randomized, open-label, multicenter Phase 3 trial designed to evaluate whether atebimetinib, an investigational, once-daily oral deep cyclic inhibitor of MEK, in combination with mGnP can improve overall survival compared with standard-of-care gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic PDAC.

The trial builds on encouraging results from Immuneering’s ongoing Phase 2a study of atebimetinib in combination with mGnP, which were reported at ASCO in June and demonstrated median overall survival of 17.3 months, median progression-free survival of 8.3 months, an objective response rate of 36% and a disease control rate of 82% among 55 patients. These results compare favorably with historical outcomes for standard GnP, although the studies were not conducted head-to-head.

“Pancreatic cancer remains one of the most difficult cancers to treat, and patients with metastatic disease in the first-line setting urgently need new therapies capable of delivering meaningful improvements in survival,” said Ben Zeskind, Ph.D., Co-founder and Chief Executive Officer of Immuneering. “Our encouraging Phase 2a results reported at ASCO, including median overall survival of 17.3 months in first-line pancreatic cancer patients, provide a strong foundation for MAPKeeper 301. This pivotal Phase 3 trial is designed to determine whether atebimetinib, in combination with modified chemotherapy, can extend survival compared with the current standard of care. We believe atebimetinib’s differentiated Deep Cyclic Inhibition mechanism, designed to shrink tumors durably, preserve body mass, and minimize side effects, has the potential to transform the treatment of metastatic pancreatic cancer.”

ESMO Congress 2026 Poster Presentation Details:

Title: MAPKeeper 301: A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus Standard Gemcitabine and nab-Paclitaxel for Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Abstract Number: 3189TiP
Presentation Type: Trial in Progress
Presentation Date: October 25, 2026
The poster will be available on the publications section of Immuneering’s website following presentation at https://immuneering.com/publications

About MAPKeeper 301

MAPKeeper 301 is a global, randomized, open-label, multicenter Phase 3 clinical trial evaluating atebimetinib in combination with modified gemcitabine and nab-paclitaxel compared with standard gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.

Patients are randomized 1:1 to receive either:

Experimental arm: Atebimetinib 320 mg orally once daily in combination with modified gemcitabine 1,000 mg/m² and nab-paclitaxel 125 mg/m², administered on days 1 and 15 of each 28-day cycle.Control arm: Standard-of-care gemcitabine 1,000 mg/m² and nab-paclitaxel 125 mg/m², administered weekly for three consecutive weeks followed by one week off. Randomization is stratified by geography, presence of liver metastases, Eastern Cooperative Oncology Group (ECOG) performance status, and whether metastatic disease is newly diagnosed or recurrent.

The primary endpoint is overall survival. Secondary endpoints include progression-free survival, overall response rate, disease control rate, safety, and quality of life.

Eligible patients must have confirmed metastatic pancreatic adenocarcinoma, measurable disease and an ECOG performance status of 0 or 1 and must not have received prior systemic anticancer therapy.

The study began dosing patients in June 2026 and is currently recruiting patients. Additional information is available at www.mapkeeper301.com and ClinicalTrials.gov (NCT07562152).

About Immuneering Corporation

Immuneering is a late-stage clinical oncology company dedicated to keeping cancer patients alive and helping them thrive, with an initial focus on patients with RAS, RAF, and other MAPK-driven cancers. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company’s development pipeline also includes additional combination opportunities and preclinical stage programs. For more information, please visit www.immuneering.com.

Forward-Looking Statements

This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: the treatment potential of atebimetinib, alone or in combination with other agents to treat cancer including modified Gemcitabine/nab-paclitaxel (mGnP); the Phase 2a results presented at ASCO providing a strong foundation for the MAPKeeper 301 trial; the unmet need and that patients with metastatic disease urgently need new therapies capable of delivering meaningful improvements in survival; the trial design, enrollment progress, and timing of results from the MAPKeeper 301 trial.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we are a late-stage clinical oncology company with a limited operating history and have not completed any registrational clinical trials; we have incurred significant losses, are not currently profitable and may never become profitable; limitations on our cash runway and potential increases in expenditures; our need for additional funding; our unproven approach to therapeutic intervention; our ability to address regulatory questions and changing regulatory standards, and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including the uncertainty of whether positive preclinical or early clinical efficacy and safety results are confirmed in later-stage trials, potential delays in activation of trial sites or enrollment of trial participants, or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.

These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended June 30, 2026, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor Contact:
Laurence Watts
New Street Investor Relations
[email protected]

Media Contact:
David Caouette
[email protected]

DALLAS, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Strive, Inc. (Nasdaq: ASST; SATA; SATS) (“Strive” or the “Company”) today announced that it has entered into a sales agreement pursuant to which Strive may issue and sell shares of its 15.00% Series A Perpetual SATS Preferred Stock, $0.001 par value per share (the “SATS Stock”), having an aggregate offering price of up to $1.0 billion (the “ATM Program”).

Strive intends to use the net proceeds from the ATM Program for general corporate purposes, including, among other things, the acquisition of bitcoin and bitcoin-related products and for working capital, the purchase of income generating assets to grow the Company’s business, other capital expenditures, and/or repurchases of shares of the Company’s Class A common stock, par value $0.001 per share (the “Class A Common Stock”) or its Variable Rate Series A Perpetual Preferred Stock, par value $0.001 per share (the “SATA Stock”). Strive may also use such proceeds to fund acquisitions of businesses, assets or technologies that complement our current business, for the payment of cash dividends declared or expected to be declared by Strive’s board of directors from time to time on shares of any class or series of Strive’s preferred stock then outstanding, or for repayment of future indebtedness.

The SATS Stock, subject to the terms and conditions of the sales agreement, may be sold by the sales agents by any method that is deemed an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended or any other method permitted by law.

The sale of SATS Stock under the ATM Program is only offered pursuant to a prospectus supplement, filed with the Securities and Exchange Commission on October 26, 2026 under the existing automatic shelf registration statement, which became effective on September 15, 2025 (File No. 333-290252), and the base prospectus contained therein.

About Strive

Strive is a structured finance company focused on disciplined capital allocation and long-term value creation. We have strategically adopted bitcoin as our hurdle rate for capital deployment because of our fiduciary duty to maximize long-term value for stockholders and compound purchasing power over time.

Strive Asset Management, LLC, a direct, wholly owned subsidiary of Strive and an SEC-registered investment adviser, manages over $2.8 billion in assets.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements herein may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 175 promulgated thereunder, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 3b-6 promulgated thereunder, which statements involve inherent risks and uncertainties. Examples of forward-looking statements include, but are not limited to, express or implied statements regarding the outlook and expectations of Strive and its subsidiaries, the strategic benefits and financial benefits of the merger transaction with Semler Scientific, Inc. (the “merger transaction”), including the expected impact of the merger transaction on Strive’s future financial performance and the ability to successfully integrate the combined businesses, and the anticipated use of proceeds from the offering. Such statements are often characterized by the use of qualified words (and their derivatives) such as “may,” “will,” “anticipate,” “could,” “should,” “would,” “believe,” “contemplate,” “expect,” “estimate,” “continue,” “plan,” “project,” “predict,” “potential,” “assume,” “forecast,” “target,” “budget,” “outlook,” “trend,” “guidance,” “objective,” “goal,” “strategy,” “opportunity,” and “intend,” as well as words of similar meaning or other statements concerning opinions or judgments of Strive and its management team about future events. Forward-looking statements are based on assumptions as of the time they are made and are subject to risks, uncertainties and other factors that are difficult to predict with regard to timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results expressed or implied by such forward-looking statements as a result of various important factors. Other risks, uncertainties and assumptions, include, among others, the following:

the outcome of any legal proceedings that may be instituted against Strive or its subsidiaries;the possibility that the anticipated benefits of the merger transaction are not realized when expected or at all, including as a result of changes in, or problems arising from, implementation of Bitcoin treasury strategies and risks associated with Bitcoin and other digital assets, general economic and market conditions, interest and exchange rates, monetary policy, and laws and regulations and their enforcement;the diversion of management’s attention from ongoing business operations and opportunities;dilution caused by Strive’s issuance of additional shares of its SATS Stock, Class A Common Stock or SATA Stock;potential adverse reactions of Strive’s clients and customers or changes to business or employee relationships, including those resulting from the completion of the merger transaction; andother factors that may affect future results of Strive or the future trading performance of its SATS Stock, Class A Common Stock or SATA Stock. These factors are not necessarily all of the factors that could cause Strive’s actual results, performance or achievements to differ materially from those expressed in or implied by any of the forward-looking statements. Other factors, including unknown or unpredictable factors, also could harm Strive’s results.

Although Strive believes that its expectations with respect to forward-looking statements are based upon reasonable assumptions within the bounds of its existing knowledge of its business and operations, there can be no assurance that the actual results of Strive will not differ materially from any projected future results expressed or implied by such forward-looking statements. Additional factors that could cause results to differ materially from those described above can be found in Strive’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and quarterly reports on Form 10-Q, and other documents subsequently filed by Strive with the SEC.

The actual results anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on Strive or its businesses or operations. Investors are cautioned not to rely too heavily on any such forward-looking statements. Forward-looking statements contained in this press release speak only as of the date hereof, and Strive undertakes no obligation to update or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by applicable law.  

No Offer or Solicitation

This press release is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Strive Media Contact:
[email protected]

Investor Contact:
[email protected]

Source: Strive, Inc.

SAN RAFAEL, Calif., Oct. 26, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, November 2, 2026, at 4:30 p.m.

WOOD DALE, Ill., Oct. 26, 2026 /PRNewswire/ -- AAR CORP.

Schemes expected to become effective October 27, 2026; new Critical Metals Corp shares expected to begin trading on Nasdaq November 6, 2026  | Source: Critical Metals Corp

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Critical Metals Corp. (Nasdaq: CRML) (“Critical Metals Corp” or the “Company”), a leading critical minerals exploration and mining company, today announced that the Supreme Court of Western Australia (the “Court”) has approved the Company’s proposed acquisition of European Lithium Limited (ASX: EUR, FRA: PF8, OTC: EULIF) (“European Lithium”).

Under the proposed transaction, Critical Metals Corp would acquire 100% of the issued share capital of European Lithium and all of European Lithium’s listed options by way of Court-approved schemes of arrangement under Part 5.1 of the Australian Corporations Act 2001 (Cth), comprising a scheme between European Lithium and its shareholders (the “Share Scheme”) and a scheme between European Lithium and the holders of its listed options (ASX: EUROC) (the “Option Scheme”, and together with the Share Scheme, the “Schemes”). The consideration payable under each Scheme is to be satisfied by the issue of new ordinary shares in Critical Metals Corp.

Court Approval

European Lithium has announced that on October 26, 2026, the Court made orders approving the Schemes. The approval follows the vote by European Lithium shareholders and option holders in favor of the Schemes on October 22, 2026.

Critical Metals Corp intends to rely on the Court’s approval of the Schemes to qualify for the exemption from registration under section 3(a)(10) of the U.S. Securities Act of 1933, as amended, in connection with the issue of new Critical Metals Corp shares under the Schemes.

Effective Date and Implementation

The Schemes will become legally effective once an office copy of the Court orders is lodged with the Australian Securities and Investments Commission, which European Lithium expects to do on October 27, 2026. Trading in European Lithium shares and options on the ASX is expected to be suspended from the close of trading that day.

The remaining key dates are expected to be:

October 27, 2026: Effective date and last day of trading of European Lithium shares and options on the ASXOctober 29, 2026: Record date for entitlements to the scheme considerationNovember 5, 2026: Implementation date, issue of new Critical Metals Corp shares to European Lithium securityholdersNovember 6, 2026: New Critical Metals Corp shares expected to begin trading on Nasdaq, and European Lithium removed from the ASX Official List All dates refer to time in Perth, Western Australia, are indicative only and subject to change. Any changes will be announced by European Lithium on the ASX. For further details, including the full timetable and next steps, please refer to European Lithium’s announcement to the ASX, “Court Approval of Schemes,” dated October 26, 2026.

About Critical Metals Corp.

Critical Metals Corp (Nasdaq: CRML) is a leading mining development company focused on critical metals and minerals, and producing strategic products essential to electrification and next-generation technologies for Europe and its Western world partners. Its flagship Project, Tanbreez, is one of the world's largest rare earth deposits and is located in Southern Greenland. The deposit is expected to have access to key transportation outlets as the area features year-round direct shipping access via deep water fjords that lead directly to the North Atlantic Ocean.

Another key asset is the Wolfsberg Lithium Project located in Carinthia, 270 km south of Vienna, Austria. The Wolfsberg Lithium Project is the first fully permitted mine in Europe and is strategically located with access to established road and rail infrastructure and is expected to be the next major producer of key lithium products to support the European market. Wolfsberg is well positioned with offtake and downstream partners to become a unique and valuable asset in an expanding geostrategic critical metals portfolio.

With this strategic asset portfolio, Critical Metals Corp is positioned to become a reliable and sustainable supplier of critical minerals essential for defense applications, the clean energy transition, and next-generation technologies in the western world.

For more information, please visit https://www.criticalmetalscorp.com/.

Cautionary Note Regarding Forward Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements may include expectations of our business and the plans and objectives of management for future operations, including with respect to the proposed acquisition of European Lithium and the anticipated timetable for and implementation of the Schemes. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this news release, forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target,” “designed to” or other similar expressions that predict or indicate future events or trends or that are not statements of historical facts. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors discussed under the “Risk Factors” section in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission. These forward-looking statements are based on information available as of the date of this news release, and expectations, forecasts and assumptions as of that date, involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Critical Metals Corp.

Investor Relations: [email protected]
Media: [email protected]

Elon Musk's Space Exploration Technologies (SPCX +1.89%), better known as SpaceX, has spent 2026 rewriting Wall Street's record books. Its June 12 initial public offering (IPO) raised $85.7 billion, including the underwriters' overallotment, and valued SpaceX at $1.77 trillion. Both are never-before-seen figures.

But SpaceX's history-making moments aren't always beneficial to its investors. While early investors have made a fortune, retail investors may pay the price for this success.

Image source: Getty Images.

Space Exploration Technologies' debut as a public company has hardly been conventional. In addition to pricing its shares several days before its June 12 debut, the company's prospectus outlined a staggered and accelerated share lockup period for early-release-eligible insiders.

Typically, companies going public prevent their insiders (high-ranking executives, board members, and early investors) from selling shares for 180 calendar days after the IPO. This ensures that insiders don't take advantage of retail investor euphoria early on.

However, SpaceX is allowing some of its insiders to sell their shares at several earnings- and time-based events through mid-December. CEO Musk, who's SpaceX's largest shareholder, is not among these early-release-eligible insiders.

Great look at the SpaceX shares unlock schedule as well as the potential passive buying schedule from @JSeyff @FrancisSharoon Depending on the early post-IPO returns, this could really play with and disperse the returns of "passive" funds (which is why there's arguably no such thing as passive). $SPCX

— Eric Balchunas (@EricBalchunas) May 28, 2026
Two business days after each of SpaceX's quarterly earnings reports, up to 911.5 million shares became eligible for sale. With the company unveiling its third-quarter operating results on Oct. 20, roughly 911.5 million shares became newly eligible for sale on Oct. 22.

Several time-based events also allow insiders to sell approximately 319 million shares each time. These events occur on calendar days 70, 90, 105, 120, 135, and 180. Given that calendar day 135 landed on a weekend (Oct. 24), today, Oct. 26, marks the release of another 319 million shares for sale by early-release-eligible insiders.

Image source: Getty Images.

We're witnessing a dubious wealth transfer in real timeBut this ongoing and accelerated share lockup period for select insiders isn't the only dubious history being made by Musk's company.

When Space Exploration Technologies went public, it sold roughly 555.6 million shares. While this might sound like a lot, it represents less than 5% of SpaceX's outstanding shares (OS). Usually, private companies going public sell anywhere from 10% to 25% of their OS.

SpaceX selling such a small percentage of its OS created a favorable environment for its stock in the weeks after its IPO. Gaining fast-track entry into the Nasdaq-100, Russell 1000, and Russell 3000 meant that passive funds scooped up a significant portion of the company's float (tradable shares). This artificially low float initially buoyed SpaceX's stock.

SPCX Space Exploration Technologies$147.49+$2.74 (+1.89%)

NASDAQ · As of 4:00 PM ET 10/23/26

However, with each earnings- and time-based insider share-unlock event, SpaceX's float is rapidly rising. Although this doesn't guarantee that insiders are cashing out, keep in mind that the overwhelming majority of these early investors haven't had any avenues to cash in their chips for years, if not a decade.

What we're effectively witnessing with each successive share-unlock event is the greatest wealth transfer in Wall Street's storied history, from retail investors to SpaceX's early-release-eligible insiders. Given the laundry list of unknowns surrounding SpaceX, including the sustainability of its operating model amid its enormous cash needs, it wouldn't be surprising to see insiders ramp up their selling and weigh on the company's stock.

Triumph Capital Management lowered its position in Apple Inc. (NASDAQ: AAPL) by 2.4% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,866 shares of the iPhone maker's stock after selling 1,644 shares during the quarter.

Sawyer and Company Inc acquired a new position in shares of Meta Platforms, Inc. (NASDAQ: META) in the undefined quarter, according to its most recent disclosure with the SEC. The fund acquired 8,864 shares of the social networking company's stock, valued at approximately $6,428,000. Meta Platforms comprises approximately 2.2% of Sawyer and Company

Meta said Monday it is planning to raise a total of $95 billion to support its investments in AI infrastructure and superintelligence.

The stock was up 1.6% in premarket trading after the announcement. Nvidia, AMD and Broadcom were interested in purchasing up to $5 billion in shares, Meta said in a statement.

The tech giant will initially raise $35 billion in underwritten public equity offerings, before raising an additional $60 billion with an at-the-market program.

The news comes as hyperscalers pour record sums into the AI infrastructure buildout. Goldman Sachs estimates that AI-related capital spending could total about $7.6 trillion from 2026 through 2031, across compute, data centers and power.

Meta's planned investments will support "emerging AI opportunities" including its family of apps, its AI agent Muse and its data center business, the company said Monday.

It plans to balance funding for these investments through a mix of operating cash flow, investment-grade debt, partnerships and equity capital.

Meta racing to secure AI infrastructureMeta is among the major hyperscalers that are increasingly tapping debt to fund the expensive infrastructure required for the AI boom.

Last week, Meta posted third-quarter results showing revenue jumped 26% year-on-year: $64.60 billion versus the $63.37 billion analysts expected. However, investors focused more on the tech company's negative free cash flow and its higher full-year capital expenditure forecast.

It now expects its full-year capex to range from $135 billion to $145 billion, raising the bottom of the range from $130 billion. That sent shares lower on the day.

Meta is building four "superclusters" with more than one gigawatt of capacity each and is on track to nearly double total infrastructure capacity in 2026 on a year-over-year basis, the company said.

The decision to raise more money "reflects the eye-watering levels of investment required to keep up in the AI arms race," Ben Wood, senior partner at CCS Insight, told CNBC. 

"Meta offering more stock comes at a time when numerous companies, such as Google, SpaceX and soon, Anthropic, are going to the markets to raise funds."

Alphabet, Google's parent company, said it would look to raise $85 billion in June. SpaceX has closed a $40 billion debt financing to purchase graphics processing units. Anthropic is preparing for an IPO.

TikTok U.S. is looking to secure multiple gigawatts of computing capacity over the coming years, CNBC reported on Friday.

Meta says share sale will support its “continued investment in AI infrastructure and personal superintelligence”, as Elon Musk warns some AI cloud computing firms face ‘guppy-level death'

You are now leaving Barron's websiteBy clicking on the “Proceed” button below, you will be redirected to a third-party website owned and operated by Hong Kong Tiimoot Information Technology Co., Limited. (“HKT”), which is located in Hong Kong. That website operates independently from Barron's and Barron's does not control the website. The privacy practices of HKT are subject to its Privacy Statement, so please read it closely. We are not responsible for HKT's privacy or other data-related practices.

Gibbs Wealth Management lifted its holdings in shares of SpaceX (NASDAQ: SPCX) by 158.2% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,428 shares of the company's stock after purchasing an additional 3,938 shares during the quarter. Gibbs Wealth Management's holdings in SpaceX were

Barclays analyst Dan Levy was the latest institutional expert to revise his position toward Tesla (NASDAQ: TSLA) stock following its impressive third-quarter (Q3) earnings.

Indeed, on Monday, October 26, he replaced his previous ‘Equal Weight’ – ‘Hold’ – rating with ‘Overweight’ – ‘Buy’ – and increased his 12-month price target for TSLA shares from $370 – effectively a 0.60% drop from the latest close at $372.22 – to $450 – a 20.90% upside.

According to the Wall Street expert’s note, the change was motivated by the assessment that the potential merger between SpaceX (NASDAQ: SPCX) and Tesla could bring a premium to the car maker’s equity, but also by various business and technological developments.

Levy cited a ‘sharp inflection in Robotaxi miles driven,’ rising adoption of FSD – the company’s self-driving technology – strong energy growth, and improvements in demand as additional bullish factors.

Analysts revise Tesla (TSLA) stock price for the next 12 months Meanwhile, Barclays’ optimistic reassessment of Tesla stock was largely in line with the rating revisions the electric vehicle (EV) maker saw following the earnings though, notably, the wider outlook for TSLA remains mixed.

Overall, Wall Street views Elon Musk’s older public company as a ‘Moderate Buy’ with fourteen positive, eleven ‘Hold’, and two ‘Sell’ recommendations, per the data Finbold retrieved from TipRanks on October 26.

The average price target for Tesla stock for the next 12 months is, however, somewhat more optimistic and stands at $414.25 – 11.29% above the latest close.

Wall Street sets Tesla stock price target for the next 12 months. Source: TipRanks Additionally, the most recent ratings and forecasts came in as almost universally bullish with new share price estimates generally standing above $400. 

This trend is also visible with the analysts who still view TSLA shares as a ‘Hold’, with, for example, JPMorgan’s (NYSE: JPM) Rajat Gupta raising the estimate from $415 to $430 on October 22, and both Jefferies and CLSA opting for exactly $400 on the same day.

Tesla stock price performance Finally, despite volatility moving the equity in both directions, the recent movements ensured that Tesla stock was, at its latest close at $372.22, 4.13% in the green on the 30-day chart and 4.93% above the October 16 lows.

Tesla stock price one-month chart. Source: Google Still, despite the improving trend, TSLA remains 15.03% down year-to-date (YTD) and 17.73% in the red in the last 12 months.

Featured image via Shutterstock

Best Crypto Exchange for Intermediate Traders and Investors

Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

Copy top-performing traders in real time, automatically.

eToro USA is registered with FINRA for securities trading.

30+ million Users worldwide

eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more.

Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!

You are now leaving Barron's websiteBy clicking on the “Proceed” button below, you will be redirected to a third-party website owned and operated by Hong Kong Tiimoot Information Technology Co., Limited. (“HKT”), which is located in Hong Kong. That website operates independently from Barron's and Barron's does not control the website. The privacy practices of HKT are subject to its Privacy Statement, so please read it closely. We are not responsible for HKT's privacy or other data-related practices.

SummaryTesla, Inc.'s growing EV backlog amid elevated fuel prices and expanding, high-margin FSD adoption underscore TSLA's near-term thesis.As the CEO feeds the Tesla - SpaceX merger exuberance, the two entities' estimated 2026 Price/Sales of 22.19x is expensive compared to NVDA (12.37x), AAPL (10.63x), and AMZN (3.23x).Regulatory/execution merger risks loom large, with a spin-off of TSLA's Chinese operations and a premium buyout price in cash/stock being likely outcomes.To deliver the "stratospheric growth," more capital and capex/cash flow pains may be necessary before the realization of the nascent robotaxi, robotics, and foundry opportunities.TSLA remains a Sell, with a prolonged/failed merger likely to trigger downside risks amid a pessimistic stock market environment. Devrimb/iStock via Getty Images

TSLA - SPCX Merger Exuberance Since my last Sell rating in July 2026, Tesla, Inc. (TSLA, TSLA:CA) has outperformed expectations by delivering a rich >20% rally against the wider market at a single-digits gain.

Part

16.31K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of GOOG, NVDA, AMZN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The analysis is provided exclusively for informational purposes and should not be considered professional investment advice. Before investing, please conduct personal in-depth research and utmost due diligence, as there are many risks associated with the trade, including capital loss.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Tesla Inc. (NASDAQ:TSLA) gave investors a pleasant shock last week: $1.53 billion in free cash flow, or the money left over after paying for new factories and equipment.

Tesla bulls and bears have fought over the same question for two years, but one unproven catalyst is now close enough to either vindicate the optimists or expose the premium as fantasy.